Last reviewed · How we verify
Nexavar
At a glance
| Generic name | Nexavar |
|---|---|
| Also known as | Nexavar neoadjuvant treatment group |
| Sponsor | Fujian Medical University |
| Target | Citron Rho-interacting kinase, Cyclin-dependent kinase-like 2, Cyclin-dependent kinase-like 3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
- Carcinoma of thyroid
- Liver cell carcinoma
- Renal cell carcinoma
Common side effects
Key clinical trials
- A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With (Phase 3)
- A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcino (Phase 3)
- A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance (Phase 1)
- Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma) (N/A)
- Open-label, Multicentric Phase I-II Trial to Evaluate the Efficacy and Safety of the Combination of Sorafenib (BAY 43-9006), Gemcitabine and Concurrent Radiotherapy, in Locally Advanced Pancreatic Car (Phase 1)
- A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer (Phase 2)
- A Phase II Study of Single Agent Sorafenib in Non-small Cell Lung Cancer Patients Who Never Smoked or Were Former Light Smokers. (Phase 2)
- Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006) (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nexavar CI brief — competitive landscape report
- Nexavar updates RSS · CI watch RSS
- Fujian Medical University portfolio CI